Comments to the study Dasatinib 140 mg once daily vs dasatinib 70 mg bid in patients with CML in accelerated phase

Abstract

Kantarjian and collaborators assessed the efficacy and safety of dasatinib in patients in accelerated phase of CML. The study confirmed the comparable efficiency and safety and relatively good tolerability in both schedules of treatment with dasatinib.

Keywords

• dasatinib
• chronic myeloid leukemia
• treatment